trending Market Intelligence /marketintelligence/en/news-insights/trending/KroeFRVyTDJ2UNLwwDbt9w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Ra Pharmaceuticals' stockholders approve $2.1B acquisition by Belgium's UCB

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Ra Pharmaceuticals' stockholders approve $2.1B acquisition by Belgium's UCB

Ra Pharmaceuticals Inc.'s stockholders approved the company's acquisition by Brussels-based UCB SA, a deal valued at $2.1 billion.

Cambridge, Mass.-based Ra Pharmaceuticals said the merger agreement was approved at a special meeting of stockholders held Dec. 17.

Under the agreement, UCB is acquiring Ra Pharmaceuticals, an autoimmune disease therapy developer, for $48 per share in cash.

The boards of both companies have already approved the deal.

The acquisition is expected to close by the end of the first quarter of 2020, subject to regulatory approval.

Bank of America Merrill Lynch and Lazard are financial advisers, while Covington & Burling LLP is the legal adviser to UCB.

Centerview Partners is the exclusive financial adviser, while Latham & Watkins LLP is legal adviser to Ra Pharmaceuticals.